Merdury Biopharmaceutical Corporation (6932) Stock Statistics & Valuation Metrics
Total Valuation
Merdury Biopharmaceutical Corporation has a market cap or net worth of TWD 2.22B. The enterprise value is ―.
- Market Cap
- TWD 2.22B
- Enterprise Value
- ―
Share Statistics
Merdury Biopharmaceutical Corporation has 432,596,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 432,596,100
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Merdury Biopharmaceutical Corporation’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -26.22%.
- Return on Equity (ROE)
- -0.31
- Return on Assets (ROA)
- -0.24
- Return on Invested Capital (ROIC)
- -26.22%
- Return on Capital Employed (ROCE)
- -0.27
- Revenue Per Employee
- 0
- Profits Per Employee
- -3.20M
- Employee Count
- 21
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Merdury Biopharmaceutical Corporation is -45.86. Merdury Biopharmaceutical Corporation’s PEG ratio is -1.42.
- PE Ratio
- -45.86
- PS Ratio
- 0.00
- PB Ratio
- 12.28
- Price to FCF
- -40.66
- Price to Operating Cash Flow
- -53.63
- PEG Ratio
- -1.42
Income Statement
In the last 12 months, Merdury Biopharmaceutical Corporation had revenue of 0 and earned -67.23M in profits. Earnings per share was -0.16.
- Revenue
- 0
- Gross Profit
- -11.64M
- Operating Income
- -68.55M
- Pretax Income
- -67.17M
- Net Income
- -67.23M
- EBITDA
- -56.91M
- Earnings Per Share (EPS)
- -0.16
Cash Flow
In the last 12 months, operating cash flow was -45.99M and capital expenditures -11.12M, giving a free cash flow of -57.11M billion.
- Operating Cash Flow
- -45.99M
- Free Cash Flow
- -57.11M
- Free Cash Flow per Share
- -0.13
Dividends & Yields
Merdury Biopharmaceutical Corporation pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.55%
- Earnings Yield
- -2.17%
Stock Price Statistics
- Beta
- 0.54
- 52-Week Price Change
- -48.60%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 32.48
- Average Volume (3m)
- 533.10K
Financial Position
Merdury Biopharmaceutical Corporation as a current ratio of 8.84, with Debt / Equity ratio of 19.02%
- Current Ratio
- 8.84
- Quick Ratio
- 8.84
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.20
- Interest Coverage Ratio
- -76.33
Taxes
In the past 12 months, Merdury Biopharmaceutical Corporation has paid 61.00K in taxes.
- Income Tax
- 61.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Merdury Biopharmaceutical Corporation EV to EBITDA ratio is -53.47, with an EV/FCF ratio of -38.50.
- EV to Sales
- 0.00
- EV to EBITDA
- -53.47
- EV to Free Cash Flow
- -38.50
- EV to Operating Cash Flow
- -47.81
Balance Sheet
Merdury Biopharmaceutical Corporation has TWD 136.49M in cash and marketable securities with TWD 42.80M in debt, giving a net cash position of TWD 93.69M billion.
- Cash & Marketable Securities
- TWD 136.49M
- Total Debt
- TWD 42.80M
- Net Cash
- TWD 93.69M
- Net Cash Per Share
- TWD 0.22
- Tangible Book Value Per Share
- TWD 0.43
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Merdury Biopharmaceutical Corporation is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- 27.60%
